Hansa Biopharma's Award Signals New Hope in Transplant Medicine

LUND, Sweden – January 22, 2026 – Hansa Biopharma has been awarded the prestigious 2025 SwedenBIO Award, a significant recognition that highlights the company's transformative impact on global medicine and its emergence as a commercial powerhouse in the life sciences sector. The award, presented at the SwedenBIO Summit in Stockholm, celebrates the Lund-based company's pioneering enzyme technology that is providing life-saving options for transplant patients who previously had none.

This honor arrives at a pivotal moment for Hansa, as it navigates a critical year marked by high-stakes regulatory reviews in the United States and ongoing clinical trials that could expand the reach of its innovative therapies. The award not only validates the company's scientific achievements but also casts a spotlight on the strength and global competitiveness of Sweden's entire life science ecosystem.

A Beacon for Swedish Innovation

Since its founding in 2007, the SwedenBIO Award has been a barometer for excellence in the nation's vibrant life science industry, recognizing companies that blend meaningful scientific progress with operational and commercial success. In selecting Hansa Biopharma, the jury emphasized the company's role as a "bold guiding star" for its ability to convert Swedish scientific discovery into tangible global health solutions and build the commercial infrastructure necessary to deliver them.

The core of this recognition lies in Hansa's proprietary IgG-cleaving enzyme technology, which has revolutionized the prospects for highly sensitized patients awaiting organ transplants. By advancing this breakthrough innovation and delivering robust clinical results, Hansa bolsters Sweden's reputation as a leader in medical innovation.

"I am truly delighted and deeply honored to receive this award on behalf of everyone at Hansa Biopharma," said CEO Renée Aguiar-Lucander upon accepting the honor. "This recognition reflects the great momentum we've built heading into 2026—powered by our strong U.S. Phase 3 data, the upcoming FDA review process, and the anticipated Phase 3 readout from our European Phase 3 trial later this year."

The Science of Second Chances

At the heart of Hansa Biopharma's success is imlifidase, a first-in-class enzyme therapy marketed in Europe as Idefirix. The treatment addresses one of the most formidable challenges in transplantation: patient sensitization. A significant portion of patients on transplant waiting lists have developed high levels of antibodies, particularly immunoglobulin G (IgG), against potential donors. These antibodies act as a biological defense system, poised to attack and reject a new organ, making it nearly impossible to find a compatible match.

Imlifidase works by rapidly and effectively cleaving these IgG antibodies, temporarily disabling this immune barrier. This creates a window of opportunity for a life-saving transplant to proceed, offering a chance at a new life for patients who might otherwise remain on dialysis indefinitely with a poor prognosis. The treatment represents a paradigm shift from waiting for a rare compatible organ to making the patient compatible with an available organ.

The clinical significance of this approach was powerfully reinforced in September 2025, when Hansa announced that its U.S. Phase 3 ConfIdeS trial for imlifidase in kidney transplantation had successfully met its primary endpoint. This positive outcome paved the way for the company's Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) in December 2025, setting the stage for a potential U.S. market launch later this year.

Navigating a Pivotal Year

The SwedenBIO Award provides a welcome tailwind as Hansa navigates a complex and consequential period. While the promise of its technology is clear, the company's financial performance has reflected the challenges of a commercial-stage biotech. In the third quarter of 2025, Hansa reported a year-over-year decline in revenue, and its stock price has faced pressure, reflecting investor sensitivity to both clinical milestones and commercial uptake.

All eyes are now on the upcoming FDA review of imlifidase. A successful approval and launch in the vast U.S. market would be a transformative commercial catalyst, validating the company's long-term strategy and providing the financial resources to fuel its broader pipeline. The company's journey also illustrates the inherent risks of biopharmaceutical development. In December 2025, a pivotal trial of imlifidase in the rare autoimmune condition anti-GBM disease did not meet its primary endpoint. Despite this, the data showed that a remarkable 60% of treated patients avoided dialysis at six months—a significant clinical improvement over the historical average of 20-25%, though a similar response in the control arm prevented the trial from achieving statistical significance.

This mixed result underscores the challenging nature of clinical research but does not detract from the proven efficacy of the platform in its primary indication of transplantation. Analysts maintain a generally positive outlook, with many seeing the current stock valuation as an opportunity in light of the major upcoming regulatory and clinical catalysts in 2026.

Beyond Transplantation: A Pipeline for the Future

While kidney transplantation remains its flagship success, Hansa is actively exploring the potential of its enzyme technology across a range of serious immune disorders. The company has reported positive Phase 2 results for imlifidase in Guillain-Barré Syndrome (GBS), a severe neurological disorder where the immune system attacks the nerves. The study showed that patients treated with imlifidase experienced faster recovery and were significantly more likely to be able to walk unaided compared to those on standard therapy alone.

Building on this promise, Hansa is advancing HNSA-5487, a next-generation enzyme engineered for enhanced potency, which is also being developed for GBS. Furthermore, the company is pioneering the use of its technology to enable the redosing of gene therapies—a major challenge in a field where a patient's immune response to the initial treatment can prevent subsequent, potentially necessary, doses. An upcoming meeting with the FDA in the first half of 2026 is expected to clarify the clinical development path for this high-potential application.

A Symbol of a Thriving Ecosystem

Hansa Biopharma's journey from a university spin-off to an award-winning commercial entity is emblematic of the strength of Sweden's life science ecosystem. The nation has cultivated a fertile ground for innovation, supported by a national strategy launched in 2024 to become a world-leading life science hub. This strategy focuses on strengthening clinical trials, digital health infrastructure, and the translation of academic research into patient benefit.

As a key player in an industry that accounts for nearly 10% of Sweden's total exports, Hansa's success story serves as a powerful case study. It demonstrates how a combination of world-class science, strategic government support, and entrepreneurial vision can create a company capable of competing on the global stage and delivering solutions to some of medicine's most pressing unmet needs. The 2025 SwedenBIO Award is not just a recognition of past achievements but an affirmation of the bright future ahead for both Hansa Biopharma and the innovative ecosystem from which it emerged.